<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946682</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVE</org_study_id>
    <nct_id>NCT04946682</nct_id>
  </id_info>
  <brief_title>Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment</brief_title>
  <official_title>Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wen-hong Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Encephalitis and meningitis are serious central nervous system diseases. There is currently a&#xD;
      lack of comprehensive and accurate diagnosis and treatment pathways. Therefore, we conducted&#xD;
      this multicenter, prospective, and randomized controlled study. It was designed to evaluate&#xD;
      the diagnostic performance and its impact on the outcomes of the patients enrolled. As such,&#xD;
      we came to the results of the optimal process of diagnosis and treatment strategy of&#xD;
      encephalitis/meningeal syndromes with improved effective treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change Modified Rankin Scale (mRS) at 1 year</measure>
    <time_frame>mRS should be measured at 1 year</time_frame>
    <description>The Modified Rankin Scale at 1 year Grade Description 0 No symptoms&#xD;
Minor symptoms not interfering with lifestyle&#xD;
Symptoms that lead to some restriction in lifestyle, but do not interfere with the patients' ability to look after themselves&#xD;
Symptoms that restrict lifestyle and prevent totally independent living&#xD;
Symptoms that clearly prevent independent living, although the patient does not need constant care and attention&#xD;
Totally dependent, requiring constant help day and night</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate at 1 year</measure>
    <time_frame>Mortality rate at 1 year</time_frame>
    <description>Mortality rate at 1 year</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time required from 1 day of admission to the initiation of the target treatment</measure>
    <time_frame>Baseline (The time point of getting the target treatment - the time point of admission)</time_frame>
    <description>The time required for the patients to get the target treatment from 1 day of admission.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">484</enrollment>
  <condition>Encephalitis</condition>
  <condition>Meningitis</condition>
  <condition>Meningoencephalitis</condition>
  <condition>Next-Generation Sequencing</condition>
  <condition>Polymerase Chain Reaction</condition>
  <arm_group>
    <arm_group_label>Group of mNGS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group of PCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Types of etiological diagnostic methods</intervention_name>
    <description>In Group of mNGS, all patients will be tested by meta next generation sequncing on admission, while patients in Group of PCR will be tested by polymerase chain reaction in accordance with the method in the guidelines.</description>
    <arm_group_label>Group of PCR</arm_group_label>
    <arm_group_label>Group of mNGS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with suspected meningitis : the patient has a new fever (&gt;38.5℃), accompanied&#xD;
             by ≥1 of the following manifestations：&#xD;
&#xD;
               1. Stiff neck&#xD;
&#xD;
               2. Change in state of consciousness&#xD;
&#xD;
               3. Other signs of meningitis: such as meningeal irritation.&#xD;
&#xD;
          -  Patients with suspected encephalitis: Unexplained changes in the state of&#xD;
             consciousness for more than 24 hours (including lethargy, agitation, personality&#xD;
             changes, etc.) or accompanied by recent memory impairment, with the following ≥1&#xD;
             manifestations:&#xD;
&#xD;
               1. Fever during the course of the disease (≥ 38℃); (oral temperature)&#xD;
&#xD;
               2. Convulsions or focal neurological symptoms;&#xD;
&#xD;
               3. Increase in the number of cerebrospinal fluid cells (&gt;4*10^6/L);&#xD;
&#xD;
               4. Abnormal EEG that meets the manifestations of encephalitis and cannot be&#xD;
                  attributed to other reasons&#xD;
&#xD;
               5. Imaging suggests encephalitis (CT or MRI)&#xD;
&#xD;
          -  Have not received effective anti-infective treatment yet&#xD;
&#xD;
          -  Have an identifiable address and live in the area during treatment.&#xD;
&#xD;
          -  Suspected encephalitis/meningitis patients who are willing to participate in trial&#xD;
             treatment and follow-up and can give informed consent (if the subject is illiterate,&#xD;
             sign or hearing consent is required).&#xD;
&#xD;
          -  Willing to comply with follow-up research procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known breastfeeding or pregnancy&#xD;
&#xD;
          -  Failure to comply with treatment or follow-up time;&#xD;
&#xD;
          -  The researcher believes that there are any conditions (social or medical) that allow&#xD;
             subjects to participate in unsafe;&#xD;
&#xD;
          -  Participating in other clinical studies&#xD;
&#xD;
          -  Insufficient cerebrospinal fluid or blood samples&#xD;
&#xD;
          -  Clinically diagnosed infections, tumors or other neurological diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanliang Zhang</last_name>
      <phone>13815440366</phone>
      <email>swinburn@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanlin Zhang</last_name>
      <phone>13771710630</phone>
      <email>zhangyanlin0012006@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tingting Feng</last_name>
      <phone>13771815873</phone>
      <email>fengting3@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi No.5 People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renfang Chen</last_name>
      <phone>13621519216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Cai</last_name>
      <phone>18817821207</phone>
      <email>lilytsai1990@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Blue Cross Brain Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201101</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinghua Ye</last_name>
      <phone>15316925807</phone>
      <email>1271648050@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Zhuji, Zhejiang Province</name>
      <address>
        <city>Zhuji</city>
        <state>Zhejiang</state>
        <zip>311899</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heqing Huang</last_name>
      <phone>13858516315</phone>
      <email>zjganran@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Wen-hong Zhang</investigator_full_name>
    <investigator_title>chairman of the infectious disease department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningoencephalitis</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

